Since the 2019 global dissemination of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), scientific advancements have enabled researchers to develop different types of vaccines and other forms of prevention and treatment against coronavirus disease 2019 (COVID-19).[1] The oral cavity is related to the development of COVID-19 as it allows the virus direct access into the body.[2] [3] [4] According to the literature, clinical evidence has demonstrated that antiviral oral solutions can inactivate SARS-CoV-2 and reduce clinical symptoms and severity of COVID-19.[2] [5] [6] [7] [8] Based on previous in vitro studies employing antiviral phthalocyanine derivative (APD) solutions,[6] [9] this case series evaluated the action of an APD oral spray for viral load reduction in COVID-19 hospitalized patients.